Grifols flies on the stock market after KPMG endorses its accounts "without qualifications"

The World Madrid

Madrid

Updated Friday, March 8, 2024-09:44

Grifols

shares

soared more than 13% on the stock market around 9:20 a.m. this Friday, minutes after the blood products firm published its accounts audited by

KPMG

with an "unqualified" opinion.

Thus, Grifols led the rise of the Ibex 35 with a rise of 12.23% around 9:10 a.m., until exchanging its shares at a price of 7.782 euros, although minutes later it increased its momentum to 13.38%, with its titles at 7,862 euros.

The Catalan company has published its consolidated annual accounts for the year 2023 before the market opens, including the statement of non-financial information, with an

"unqualified"

opinion from its auditor KPMG, as reported to the National Market Commission. Securities (CNMV).

The blood products firm has explained that it has been decided to further detail the pre-existing agreement with

ImmunoTek

, and has explained to Europa Press that this does not affect the profit and loss account "as it is not material", but rather the balance sheet, that is, 96 million euros out of a total of 21.3 million, and the cash flow by 4 million.

Specifically, Grifols' total assets, including ImmunoTek and now with the audited accounts, reach 21.44 million euros, compared to the 21.32 million euros reported in the accounts dated February 29.